Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Europe Approvals Drug Review

EU Approval Decision Imminent For First CD20xCD3 Bispecific Antibody

  • News

Executive Summary

If Roche gets the nod from the European Medicines Agency for mosunetuzumab this week, it could become the first company to market a CD20xCD3 bispecific antibody for follicular lymphoma.

You may also be interested in...



Mustang’s CAR-T MB-106 Shows Potential Competitiveness In CD20 Space

The company has maintained faith in autologous CAR-Ts, and its latest data show early signs of strong efficacy and favorable tolerability, possibly enabling outpatient use.

Marketing Firsts Due As Amryt’s Filsuvez And Roche’s Lunsumio Win EU Nod

Amryt’s epidermolysis bullosa gel and Roche’s CD20xCD3 bispecific antibody for follicular lymphoma are among four drugs that have received the thumbs up from the European Medicines Agency.

Roche Seeks Speedy EU Review For Second Bispecific Antibody

The European Medicines Agency was this week deciding whether to grant accelerated assessment for glofitamab.

Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
Europe Approvals Drug Review
Latest Headlines

iPLEDGE REMS: FDA Panel To Consider Changing Pregnancy Testing, Counseling Requirements

Pink Sheet Podcast: Moderna CEO On Capitol Hill, Xtandi March-In Rights, Tofersen Adcomm In ALS

Moderna And The All-American Drug Pricing Hearing

US FDA Formalizes ‘One-Trial’ Approach For Oncology Accelerated Approval

See All
UsernamePublicRestriction

Register

PS146043

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By